secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2023-04-26T23:59:59+00:00
Accession:  0001628280-23-013290
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo cuts 27% of US workforce, restructures toward neurology and Fabry; EVP departs
--------------------------------------------------------------------------------

- US workforce reduced by ~120 roles (~27%); expects ~$31M annualized cost savings from restructuring.
- EVP Technical Operations R. Andrew Ramelmeier to leave July 10, 2023; Phillip Ramsey appointed Head of Technical Ops.
- Preliminary Q1 cash position expected to fund operations for at least 12 months; full Q1 results due by May 10, 2023.
- Strategic focus on Nav1.7 (IND 2024), prion (IND 2025), Fabry Phase 3 trial, and TX200 CAR-Treg; pauses partnered programs.
- One-time restructuring costs estimated at $5M-$7M, primarily in Q2 2023; reduces internal manufacturing and allogeneic footprints.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023013290/0001628280-23-013290-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828023013290/sgmo-20230426.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-013290

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer